3.30

2.65% -0.09

Pre-market: 3.30

Mural Oncology Plc (MURA)

Overview News Price History Discussions Forecast

Mural Oncology Plc stock is currently priced at $3.30, with a 24-hour trading volume of 108.07K. It has seen a -2.65% decreased in the last 24 hours and a -12.00% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $3.40 pivot point. If it approaches the $3.28 support level, significant changes may occur.

Previous Close:

$3.39

Open:

$3.37

24h Volume:

108.07K

Market Cap:

$55.85M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-1.20%

1M Performance:

-12.00%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1D Range:

$3.24

$3.42

52W Range:

$3.16

$6.00

Mural Oncology Plc Stock (MURA) Company Profile

Name

Mural Oncology Plc

Sector

Healthcare (1205)

Industry

Biotechnology (692)

Phone

353 1 905 8020

Address

10 EARLSFORT TERRACE, DUBLIN 2

Employee

Twitter

Next Earnings Date

Latest SEC Filings

MURA's Discussions on Twitter

Mural Oncology Plc Stock (MURA) Latest News

Mural to Present and Host 1×1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference - ForexTV.com

ForexTV.com

Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference

GlobeNewswire Inc.

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Mural Oncology plc (NASDAQ:MURA) Sees Significant Decline in Short Interest - MarketBeat

MarketBeat

Mural Oncology plc (NASDAQ:MURA) Sees Significant Decline in Short Interest - MarketBeat

MarketBeat

Closing Figures: Mural Oncology plc (MURA)'s Negative Finish at 3.35, Down -6.42 – DWinneX - The Dwinnex

The Dwinnex

Mural Oncology Plc Stock (MURA) Financials Data

There is no financial data for Mural Oncology Plc (MURA). Check out other stocks for more information.

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging their core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. The Company operates as one business segment, which is the business of developing medicines designed to address unmet medical needs of patients in the area of oncology.